The causes of the inflammation and possible therapeutic options in dialysis patients

Gulhane Medical Journal

Volumn 49, Issue 4, 2007, Pages 271-276

  Yilmaz, Mahmut Ilker ^a,b  

^a Department of Immunology

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Hemodialysis; Inflammation; Peritoneal dialysis; Therapeutic options

Indexed keywords

EID: 38349129558     PISSN: 13020471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87-92.
2. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016.
3. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476.
4. Stenvinkel P, Wanner C, Metzger TG, et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798.
5. Nascimento MM, Pecoits-Filho R, Qureshi AR, et al. The prognostic impact of fluctuating levels of C-reactive protein in Brazilian haemodialysis patients: a prospective study. Nephrol Dial Transplant 2004; 19: 2803-2809.
6. Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327-335.
7. Muntner P, Hamm LL, Kusek JW, et al. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9-17.
8. Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-2219.
9. Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003 (87): S24-31.
10. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
11. Panichi V, Maggiore U, Taccola D, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1154-1160.
12. Honda H, Qureshi AR, Heimburger O, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin A as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148.
13. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233.
14. Wang AY, Sea MM, Tang N, et al. Resting energy expenditure and subsequent mortality risk in peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: 3134-3143.
15. Miyata T, Sugiyama S, Suzuki D, et al. Increased carbonyl modification by lipids and carbohydrates in diabetic nephropathy. Kidney Int Suppl 1999; 71: S54-56.
16. Gutierrez A, Alvestrand A, Wahren J, et al. Effect of in vivo contact between blood and dialysis membranes on protein catabolism in humans. Kidney Int 1990; 38: 487-494.
17. Caglar K, Peng Y, Pupim LB, et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62: 1408-1416.
18. Schindler R, Boenisch O, Fischer C, et al.. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53: 452-459.
19. Memoli B, Postiglione L, Cianciaruso B, et al. Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients. Kidney Int 2000; 58: 417-424.
20. Carrero JJ, Axelsson J, Avesani CM, et al. Being an inflamed peritoneal dialysis patient - a Dante's journey. Contrib Nephrol 2006; 150: 144-151.
21. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol 1993; 3: 1541-1554.
22. Kaysen GA. Role of inflammation and its treatment in ESRD patients. Blood Purif 2002; 20: 70-80.
23. Rahmati MA, Craig RG, Homel P, et al. Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 2002; 40: 983-989.
24. Kshirsagar AV, Moss KL, Elter JR, et al. Periodontal disease is associated with renal insufficiency in the Atherosclerosis Risk In Communities (ARIC) study. Am J Kidney Dis 2005; 45: 650-657.
25. van Tellingen A, Grooteman MP, Schoorl M, et al. Intercurrent clinical events are predictive of plasma Creactive protein levels in hemodialysis patients. Kidney Int 2002; 62: 632-638.
26. Vicente-Martinez M, Martinez-Ramirez L, Munoz R, et al. Inflammation in patients on peritoneal dialysis is associated with increased extracellular fluid volume. Arch Med Res 2004; 35: 220-224.
27. Chung SH, Heimburger O, Stenvinkel P, et al. Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol Dial Transplant 2001; 16: 2240-2245.
28. Ozkahya M, Ok E, Cirit M, et al. Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998; 13: 1489-1493.
29. Pecoits-Filho R, Stenvinkel P, Wang AY, et al. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004; 24: 327-339.
30. Woodrow G, Turney JH, Brownjohn AM. Technique failure in peritoneal dialysis and its impact on patient survival. Perit Dial Int 1997; 17: 360-364.
31. Glorieux GL, Dhondt AW, Jacobs P, et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004; 65: 2184-2192.
32. Vanholder R, Schepers E, Meert N, et al. What is uremia? Retention versus oxidation. Blood Purif 2006; 24: 33-38.
33. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002; 17: 1814-1818.
34. Schindler R, Beck W, Deppisch R, et al. Short bacterial DNA fragments: detection in dialysate and induction of cytokines. J Am Soc Nephrol 2004; 15: 3207-3214.
35. Jaar BG, Hermann JA, Furth SL, et al. Septicemia in diabetic hemodialysis patients: comparison of incidence, risk factors, and mortality with nondiabetic hemodialysis patients. Am J Kidney Dis 2000; 35: 282-292.
36. Nassar GM, Ayus JC. Infectious complications of the hemodialysis access. Kidney Int 2001; 60: 1-13.
37. Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876.
38. Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9: 1314-1317.
39. Williams B, Layward E, Walls J. Skeletal muscle degradation and nitrogen wasting in rats with chronic metabolic acidosis. Clin Sci (Lond) 1991; 80: 457-462.
40. Nawrocki A, Scherer PE. The delicate balance between fat and muscle: adipokines in metabolic disease and musculoskeletal inflammation. Curr Opin Pharm 2004; 4: 281-289.
41. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
42. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
43. Yao Q, Axelsson J, Heimburger O, et al. Systemic inflammation in dialysis patients with end-stage renal disease: causes and consequences. Minerva Urol Nefrol 2004; 56: 237-248.
44. Stenvinkel P, Lindholm B, Heimbürger O. Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease. Semin Dial 2004; 17: 505-515.
45. Kaizu Y, Ohkawa S, Odamaki M, et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 2003; 42: 295-302.
46. Johansen Kl, Kaysen GA, Young BS, et al. Longitudinal study of nutritional status, body composition, and physical function in hemodialysis patients. Am J Clin Nutr 2003; 77: 842-846.
47. Stenvinkel P, Lindholm B, Lönnqvist F, et al. Increases in serum leptin during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303-1309.
48. Ward RA, McLeish KR. Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 1995; 5: 1697-1702.
49. Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2431-2438.
50. Ernst E, Hammerschmidt DE, Bagge U, et al. Leukocytes and the risk of ischemic diseases. JAMA 1987; 257: 2318-2324.
51. Weijenberg MP, Feskens EJ, Souverijn JH, et al. Serum albumin, coronary heart disease risk, and mortality in an elderly cohort. Epidemiology 1997; 8: 87-92.
52. Reddan DN, Klassen PS, Szczech LA, et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 1167-1173.
53. Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-2245.
54. Allende LM, Corell A, Manzanares J, et al. Immunodeficiency associated with anorexia nervosa is secondary and improves after refeeding. Immunology 1998; 94: 543-551.
55. Sjoland JA, Pedersen RS, Jespersen J, et al. Intraperitoneal heparin ameliorates the systemic inflammatory response in PD patients. Nephron Clin Pract 2005; 100: c105-110.